

# Clinical Practice Guideline: Safe Medication Use in the ICU

Sandra L. Kane-Gill, PharmD, MS, FCCM, FCCP<sup>1,2</sup>; Joseph F. Dasta, MS, FCCP, MCCM<sup>3</sup>; Mitchell S. Buckley, PharmD, FCCM, FCCP, FASHP, BCCCP<sup>4</sup>; Sandeep Devabhakthuni, PharmD, BCPS-AQ Cardiology<sup>5</sup>; Michael Liu, PharmD, BCCCP, BCNSP, BCPS<sup>6</sup>; Henry Cohen, PharmD, MS, FCCM, BCPP, CGP<sup>7,8</sup>; Elisabeth L. George, CCRN-K, MSN, PhD, RN<sup>9</sup>; Anne S. Pohlman, MSN, APN-CNS, CCRN, FCCM<sup>10</sup>; Swati Agarwal, MD<sup>11</sup>; Elizabeth A. Henneman, PhD, RN, FAAN<sup>12</sup>; Sharon M. Bejian, PharmD, BCPS<sup>13</sup>; Sean M. Berenholtz, MD, MHS, FCCM<sup>14</sup>; Jodie L. Pepin, PharmD<sup>15</sup>; Mathew C. Scanlon, MD, CPPS<sup>16,17</sup>; Brian S. Smith, PharmD<sup>18</sup>

<sup>1</sup>Department of Pharmacy and Therapeutics, Critical Care Medicine, Biomedical Informatics and Clinical Translational Science Institute, University of Pittsburgh, Pittsburgh, PA.

<sup>2</sup>Department of Pharmacy, UPMC, Pittsburgh, PA.

<sup>3</sup>Department of Pharmacy Practice and Science, The Ohio State University, College of Pharmacy, Columbus, OH.

<sup>4</sup>Department of Pharmacy, Banner University Medical Center Phoenix, Phoenix, AZ.

<sup>5</sup>Department of Pharmacy Practice and Science, University of Maryland School of Pharmacy, Baltimore, MD.

<sup>6</sup>Department of Pharmacy, Yale-New Haven Hospital, New Haven, CT.

<sup>7</sup>Department of Pharmacy Services, Touro College of Pharmacy, New York, NY.

<sup>8</sup>Kingsbrook Jewish Medical Center, Brooklyn, NY.

<sup>9</sup>UPMC-Presbyterian, Pittsburgh, PA.

<sup>10</sup>Department of Medicine, University of Chicago, Chicago, IL.

<sup>11</sup>Pediatric Critical Care, Department of Pediatrics, Inova Children's Hospital, Falls Church, VA.

<sup>12</sup>College of Nursing, University of Massachusetts Amherst, Amherst, MA.

<sup>13</sup>Inova Fairfax Hospital, Falls Church, VA.

<sup>14</sup>Departments of Anesthesia/CCM and Surgery, and Health Policy & Management, Johns Hopkins Schools of Medicine and Bloomberg School of Public Health, Baltimore, MD.

<sup>15</sup>Department of Pharmacy, Seton Medical Center Williamson, Round Rock, TX.

<sup>16</sup>Department of Pediatrics and Critical Care Medicine, Medical College of Wisconsin, Milwaukee, WI.

<sup>17</sup>Children's Hospital of Wisconsin, Milwaukee, WI.

<sup>18</sup>Department of Pharmacy, UMass Memorial Medical Center, Worcester, MA.

Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's website (<http://journals.lww.com/ccmjjournal>).

Mr. Dasta received funding from Bayer Pharma (consultant: health economics pneumonia), the Medicines Company (consultant: pain management), and he disclosed that he owns stock in Merck, Pfizer, Abbvie, Abbott Labs, Copyright © 2017 by the Society of Critical Care Medicine and Wolters Kluwer Health, Inc. All Rights Reserved.

DOI: 10.1097/CCM.0000000000002533

Bristol Myers Squibb, Eli Lilly, and Express Scripts. Dr. George participates in the American Association of Critical Care Nurses (journal article reviews for continuing education) and disclosed that she had a one-time contract with Medtronic for speaking engagement on capnography, presented at American Association of Critical Care Nurses National Training Institute May 2016. The remaining authors have disclosed that they do not have any potential conflicts of interest.

For information regarding this article, E-mail: [slk54@pitt.edu](mailto:slk54@pitt.edu)

**Objective:** To provide ICU clinicians with evidence-based guidance on safe medication use practices for the critically ill.

**Data Sources:** PubMed, Cochrane Database of Systematic Reviews, Cochrane Central Register of Controlled Trials, CINAHL, Scopus, and ISI Web of Science for relevant material to December 2015.

**Study Selection:** Based on three key components: 1) environment and patients, 2) the medication use process, and 3) the patient safety surveillance system. The committee collectively developed Population, Intervention, Comparator, Outcome questions and quality of evidence statements pertaining to medication errors and adverse drug events addressing the key components. A total of 34 Population, Intervention, Comparator, Outcome questions, five quality of evidence statements, and one commentary on disclosure was developed.

**Data Extraction:** Subcommittee members were assigned selected Population, Intervention, Comparator, Outcome questions or quality of evidence statements. Subcommittee members completed their Grading of Recommendations Assessment, Development, and Evaluation of the question with his/her quality of evidence assessment and proposed strength of recommendation, then the draft was reviewed by the relevant subcommittee. The subcommittee collectively reviewed the evidence profiles for each question they developed. After the draft was discussed and approved by the entire committee, then the document was circulated among